<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161333">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01761695</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-HEMREG-CML</org_study_id>
    <nct_id>NCT01761695</nct_id>
  </id_info>
  <brief_title>Chronic Myelod Leukemia Registry at Asan Medical Center</brief_title>
  <official_title>Prospective Observational Cohort Registry for Patients With Chronic Myeloid Leukemia at Asan Medical Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would like to propose a prospective longitudinal observational cohort
      study for patients who will be diagnosed and/or treated for chronic myeloid leukemia at Asan
      Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other
      retrospective analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Acquisition of informed concent form

        2. Data acquisition from medical record including

             -  demographic / disease-associated factors

             -  details of treatment, and its results

             -  complications during treatment

             -  genetic data

             -  survival outcome (upto 30 years)

        3. Accumulation of data for 30 years

        4. Use of data for other retrospective analysis (including Asan Medical center Cell
           Banking basic data)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2047</completion_date>
  <primary_completion_date type="Anticipated">December 2047</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>30 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>30 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Definition of events will be as 'failure', 'progress to AP/BC', 'intolerant and medication change', and 'death from any cause'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>30 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Failure will be defined as BCR-ABL elevation at 2 serial times, progression to AP/BC, loss of hematologic / cytogenetic response, any appearance of ABL kinase mutation, and clonal evolution.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1050</enrollment>
  <condition>Leukemia, Chronic Myeloid</condition>
  <condition>Myeloid Leukemia, Chronic, Accelerated Phase</condition>
  <condition>Myeloid Leukemia, Chronic, Chronic Phase</condition>
  <arm_group>
    <arm_group_label>CML CP</arm_group_label>
    <description>Diagnosed as CML with chronic phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CML AP</arm_group_label>
    <description>Diagnosed as CML with accelerated phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CML BC</arm_group_label>
    <description>Diagnosed as CML with blast crisis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CML other</arm_group_label>
    <description>Diagnosed as CML, which is not included in any of other category</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnosed as CML</intervention_name>
    <description>All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047</description>
    <arm_group_label>CML CP</arm_group_label>
    <arm_group_label>CML AP</arm_group_label>
    <arm_group_label>CML BC</arm_group_label>
    <arm_group_label>CML other</arm_group_label>
    <other_name>Diagnosed as chronic myeloid leukemia</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone marrow aspirate or peripheral blood (for its mononuclear cells) will be collected,
      processed, and cryopreserved for future analysis of DNA or cell culture. Acquisition of
      biospecimens will be proceeded if patient agree with the informed consent for donation of
      biospecimen to 'Asan Medical Center Biomaterial Resource Banking Center'. This registry data
      will be used as a basic demographic and clinical information for the biospecimens.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are diagnosed and/or treated with chronic myeloid leukemia at Asan Medical
        Center, Seoul, Korea
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who are diagnosed and/or treated as chronic myeloid leukemia at Asan
             Medical Center

          -  15 years of age and over

          -  All patients who give written consent according to guidelines at Asan Medical Center
             committee on human research

        Exclusion Criteria:

          -  Patients who refuse to give consent to registering
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae-Young Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seo Hyun Na, RN</last_name>
    <phone>82-2-3010-8261</phone>
    <email>claudiana@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seo Hyun Na, RN</last_name>
      <phone>82-2-3010-8261</phone>
      <email>claudiana@naver.com</email>
    </contact>
    <investigator>
      <last_name>Kyoo-Hyung Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dae-Young Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Je-Hwan Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung-Hee Lee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 1, 2014</lastchanged_date>
  <firstreceived_date>January 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Dae-Young Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
